Owkin exists to find the right treatment for every patient.
Our vision
To find better treatments, everything starts with a “why?”
Why do some cancer patients respond well to some drugs while others don’t?
Work with us to find the answers across four focus areas.
Discover
We combine cutting-edge machine learning and biology to identify novel drug candidates.
- Biomarkers
- Drug target identification
- Drug repurposing
- Drug combinations
Collaborate
We blend human insight with safe and fast data access to power more accurate models.
- Owkin data and KOL network
- Federated learning
- Owkin Connect
- Consortia
De-risk and accelerate
Our machine learning methodologies de-risk and accelerate clinical trials.
- External control arm
- Covariate adjustment
Diagnose
We build impactful digital pathology diagnostics to directly improve patient outcomes.
- Diagnostics
Owkin’s platform
Owkin’s platform
Our platform consists of three capabilities.
01. Data access & federated learning
We access data at scale with federated learning to preserve patient privacy and data security
03. Interpretable AI
We create interpretable AI to answer a broad range of research questions
02. Expertise in biology & medicine
We combine insights from world class experts in cancer with our in-house biological knowledge to make sense of multimodal datasets
02. Expertise in biology & medicine
We combine insights from world class experts in cancer with our in-house biological knowledge to make sense of multimodal datasets
03. Interpretable AI
We create interpretable AI to answer a broad range of research questions
We use this platform for internal R&D and make it available to partners to accelerate discovery and development projects.
Why Owkin?
150 & 30
Team of 150 (30 PhDs)
55
55 research organizations and hospitals in our network
25
25 publications in top-tier scientific journals
160 & 44
160 KOLs of which 44 have a H-index above 40
8
8 consortia with top pharma and research centers
18 & 8
18 cancers investigated with a focus on 8
200,000
Multimodal and longitudinal datasets with 200,000 patients across cohorts
ISO27001
Secure, robust and audited technology that works on traceable infrastructure. GDPR compliant
Hear from our partners
01/03
“Owkin’s unique methodology, which applies AI to patient data from partnerships with multiple academic medical centres, supports our ambition to leverage data in innovative ways in R&D. We are striving to advance precision medicine and to discover innovative treatment methods with the greatest benefits for patients.”
“Owkin combines the power of trials, labs and data science to converge towards the delivery of personalized value-based medicine. Thanks to Owkin's sophisticated computation and inference, together we have generated insights, enabling us to reason and learn, to empower our decision making.”
“Without federated learning, most biomedical data would likely remain unused and unavailable to construct the next generation of predictive algorithms.”
Join the conversation
Join the conversation
Owkin becomes ‘unicorn’ with $180m investment from Sanofi and four new collaborative projects
Read more
Attend the MELLODDY General Assembly’s online open session to learn about the consortium’s results and the potential of federated learning to advance drug discovery.
Register now
Take a closer look
